Recipient Morbidity After Living and Deceased Donor Liver Transplantation: Findings from the A2ALL Retrospective Cohort Study

Authors


  • This is publication number 8 of the Adult-to-Adult Living Donor Liver Transplantation Cohort Study.

* Corresponding author: Chris E. Freise, freisec@surgery.ucsf.edu

Abstract

Patients considering living donor liver transplantation (LDLT) need to know the risk and severity of complications compared to deceased donor liver transplantation (DDLT). One aim of the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL) was to examine recipient complications following these procedures. Medical records of DDLT or LDLT recipients who had a living donor evaluated at the nine A2ALL centers between 1998 and 2003 were reviewed. Among 384 LDLT and 216 DDLT, at least one complication occurred after 82.8% of LDLT and 78.2% of DDLT (p = 0.17). There was a median of two complications after DDLT and three after LDLT. Complications that occurred at a higher rate (p < 0.05) after LDLT included biliary leak (31.8% vs. 10.2%), unplanned reexploration (26.2% vs. 17.1%), hepatic artery thrombosis (6.5% vs. 2.3%) and portal vein thrombosis (2.9% vs. 0.0%). There were more complications leading to retransplantation or death (Clavien grade 4) after LDLT versus DDLT (15.9% vs. 9.3%, p = 0.023). Many complications occurred more commonly during early center experience; the odds of grade 4 complications were more than two-fold higher when centers had performed ≤20 LDLT (vs. >40). In summary, complication rates were higher after LDLT versus DDLT, but declined with center experience to levels comparable to DDLT.

Introduction

The introduction of right lobe adult-to-adult living donor liver transplant (LDLT) created a new treatment option for patients in need of liver replacement. The procedure is highly technical in nature, and has not yet achieved the widespread application of deceased donor liver transplant (DDLT) (1). Given the comparatively recent introduction of LDLT, comprehensive descriptions of its associated complication rates and outcomes have been published mainly in single-center reports (2–7). The Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL) includes nine U.S. transplant centers with LDLT experience that have collaboratively collected retrospective and prospective LDLT data. This report details the A2ALL retrospective cohort morbidity experience among LDLT recipients and contemporaneous patients who had potential living donors, but who ultimately received a DDLT graft.

Methods

Data collection and conventions

Data for this study were derived from the retrospective component of the A2ALL study and were supplemented by data from the Scientific Registry of Transplant Recipients (SRTR) made available through a data use agreement. A2ALL data were collected based on detailed chart reviews. Entry of a recipient into the A2ALL Retrospective Cohort Study required the identification of a potential donor who completed a history and physical examination during the period January 1, 1998 to February 28, 2003 at one of nine U.S. transplant centers. A total of 819 potential adult recipients met the inclusion criteria. The current analysis included the 600 patients who proceeded to the operating room with the intention of receiving either a LDLT or DDLT for nonfulminant indications. Recipients whose procedures were aborted due to recipient reasons were included (four LDLT; three DDLT). Recipients of domino transplants (n = 2) were included in the DDLT group.

Complications were defined as unexpected events that were not inherent to the transplant procedure. Severity of complications was graded using an adaptation of the Clavien scoring system (8–10) for the classification of negative outcomes (Table 1).

Table 1.  Clavien system for the classification of negative outcomes in general surgery and solid organ transplantation (adapted from references 8–10)
Grade 1Any alteration from the ideal postoperative course, with complete recovery or which can be easily controlled and which fulfills the following general characteristics:
(a) Not life threatening
(b) Not requiring use of drugs other than immunosuppressants, analgesics, antipyretics, antiinflammatory agents, antiemetics, drugs required for urinary retention or lower urinary tract infection, arterial hypertension, hyperlipidemia or transient hyperglycemia
(c) Requiring only therapeutic procedures that can be performed at the bedside
(d) Postoperative bleeding requiring ≤3 units of blood transfusion
(e) Never associated with a prolongation of ICU stay or total hospital stay to more than twice the median stay for the procedure in the population of the study
Grade 2Any complication that is potentially life threatening or results in ICU stay >5 days, hospital stay >4 weeks for the recipient, but which does not result in residual disability or persistent disease
Grade 3Any complication with residual or lasting functional disability or development of malignant disease
Grade 4Complications that lead to retransplantation (grade 4a) or death (grade 4b)

Statistical methods

Descriptive statistics included means, standard deviations and proportions. Mantel–Haenszel trend tests were used to compare LDLT versus DDLT for number of complications per patient and complications by grade. Chi-square tests (and Fisher's exact tests in cases of small cell sizes) were used to compare LDLT versus DDLT for the proportion with Clavien grade 4 complications and for the proportion with complications of any Clavien grade. Since similar results were obtained by log-rank tests, most events occurred during the first 30 days and most (98% of LDLT, 96% of DDLT) follow-up times were beyond 30 days, only chi-square test results were reported. Logistic regression analyses were used to investigate predictors of biliary leak, biliary stricture and Clavien grade 4 complications. Each of the variables in Table 2 was tested in each of the logistic regression models. Results are presented as adjusted odds ratios (AOR) and 95% confidence intervals (CI). In a previous A2ALL analysis of mortality, LDLT recipients were classified as having received their transplant when the center had less LDLT experience (had performed ≤20 LDLT) or more LDLT experience (had performed >20 LDLT) (11). To test the effect of center experience on complications using smaller increments, the sequential cases at each center were categorized as cases 1–10, 11–20, 21–40 and greater than 40 in the logistic regression models.

Table 2.  Characteristics of living donor (LDLT) and deceased donor liver transplant (DDLT) recipients and LDLT living donors
Recipient characteristicLDLT (n = 384); mean (SD) or n (%)DDLT (n = 216); mean (SD) or n (%)p-Value*
  1. *p-values comparing LDLT versus DDLT for continuous variables are based on t-tests, and for categorical variables are based on the chi-square or Fisher's exact tests.

  2. 1Values are missing in less than 5% for these variables.

  3. 2MELD = model for end-stage liver disease.

  4. 3Values are missing in 17%.

  5. 4N = 378; graft weight was obtained from intraoperative measurement (47%), imaging (29%), or 0.6 × donor SLV (23%) and was missing in 1%. Imaging volume was multiplied by 0.8, which was an empirical correction based on a regression analysis of actual versus imaging values.

Age49.6 ± 10.751.4 ± 9.70.037
Sex  0.649
 Female162 (42) 88 (41) 
 Male222 (58)128 (59) 
Ethnicity  0.822
 Hispanic 74 (19) 40 (19) 
 Non-Hispanic310 (81)176 (81) 
Race  0.368
 White348 (91)190 (88) 
 African American12 (3)13 (6) 
 Asian15 (4) 7 (3) 
 Other 9 (2) 6 (3) 
Body mass index1 (kg/m2)27 ± 527 ± 50.780
Diagnosis (multiple diagnoses possible)   
 Hepatitis C diagnosis (HCV)184 (48)102 (47)0.870
 Hepatocellular carcinoma diagnosis (HCC) 63 (16) 39 (18)0.606
 Alcohol 52 (14) 32 (15)0.666
 Cholestatic liver disease 71 (18) 39 (18)0.895
 Noncholestatic cirrhosis   
   other than HCV/alcohol 80 (21) 48 (22)0.690
 Acute hepatic necrosis 6 (2) 9 (4)0.050
 Metabolic disease11 (3) 7 (3)0.795
 Biliary atresia 3 (1) 0 (0)0.557
 Malignancy other than HCC11 (3) 5 (2)0.688
 Other 9 (2) 3 (1)0.551
MELD score at transplant1,2 Categorical  <0.0001 
 6–10 80 (21) 22 (10) 
 11–20229 (60)104 (48) 
 21–30 48 (13) 45 (21) 
 31–4010 (3) 41 (19) 
 Missing16 (4) 4 (2) 
 Continuous15 ± 621 ± 9<0.0001 
Medical condition at transplant Not hospitalized  <0.0001 
335 (87)130 (60) 
 Hospitalized (not ICU) 42 (11) 48 (22) 
 ICU 7 (2) 38 (18) 
Severity   
 Ventilator 5 (1)15 (7) 0.0002
 Ascites222 (58)160 (74)<0.0001 
 Dialysis 5 (1)14 (6)0.001
Intraoperative   
 Cold ischemia time (minutes)387 ± 94 441 ± 215<0.0001 
 Duration of recipient operation (minutes)1511 ± 129371 ± 96<0.0001 
LDLT living donor characteristics   
 Age 37 ± 9.7  
 Intraoperative hypotension (<100 mmHg)1 88 (23)  
 Number of donor bile ducts   
 1205 (53)  
 2135 (35)  
 ≥321 (5)  
 Missing23 (6)  
Type of anastomosis   
 Roux-en-Y199 (52)  
 Other218 (47)  
 Missing 5 (2)  
Graft weight to recipient weight ratio <0.8430 (8)  

All analyses were carried out using SAS 9.1 statistical software (SAS/STAT 9.1 User's Guide, SAS Publishing, Cary, NC: SAS Institute Inc.).

Human subjects protection

The study was approved by the Institutional Review Boards and Privacy Boards of the University of Michigan Data Coordinating Center and each of the nine participating transplant centers.

Results

The study group consisted of 384 LDLT and 216 DDLT recipients followed for a median of 2.1 years (range 0–5.9 years). The follow-up time for LDLT was longer than that for DDLT (2.2 years vs. 1.9 years, respectively; log-rank p = 0.008), although this difference had little impact on the analysis because most complications occurred within 30 days. At least 1 year of follow-up was available for 84% of LDLT and 69% of DDLT recipients. The characteristics of LDLT and DDLT recipients at the time of transplant are shown in Table 2. Compared to DDLT recipients, the LDLT recipients were slightly younger (mean age 49.6 vs. 51.4 years; p = 0.037), had less advanced liver disease (mean Model for End-stage Liver Disease [MELD] score 15 vs. 21; p < 0.0001) and were more medically stable (2% vs. 18% in ICU; p < 0.0001) at the time of transplant. The graft weight to recipient weight ratio was less than 0.8 in 30 cases (8%), with a range of 0.5–2.6.

Table 3 compares the frequencies of complications for early and later LDLT experience groups (LDLT case number ≤20 and >20) and DDLT. In the early LDLT experience group, only 9.6% of patients had no complications, compared with 23.0% among the later LDLT experience group and 21.8% among DDLT recipients. Early LDLT experience recipients tended to have a greater number of complications per patient, a median of four, compared to a median of two in the later LDLT experience group (p < 0.0001) and two in the DDLT group (p = 0.72 compared to later LDLT experience).

Table 3.  Number of complications per transplanted recipient1
Number of complications(A) LDLT case number ≤ 20 (n = 167)(B) LDLT case number > 20 (n = 217)(C) DDLT (n = 216)
Number of recipients%Number of recipients%Number of recipients%
  1. 1Mantel-Haenszel trend test comparing columns (A) versus (B): p < 0.0001 and (B) versus (C): p = 0.7216.

016 9.65023.04721.8
12112.63817.54018.5
22716.23214.73616.7
31810.82411.119 8.8
414 8.415 6.92411.1
514 8.417 7.810 4.6
611 6.611 5.1 4 1.9
715 9.0 5 2.3 8 3.7
8 7 4.2 7 3.2 7 3.2
9 9 5.4 7 3.2 5 2.3
≥1015 9.011 5.116 7.4

The specific types of complications were aggregated into three broad categories: surgical, medical and infectious. A summary of the frequency of these complications is detailed in Table 4. Recipients transplanted during periods of later (>20 cases) versus earlier (≤20 cases) LDLT center experience experienced a lower proportion of complications in almost every category. Significant reductions (all p < 0.04) with increased LDLT experience were seen with biliary leak or biloma (38% vs. 27%), unplanned reexploration (36% vs. 19%), pneumothorax (3% vs. 0%), ascites (21% vs. 9%) and overall infections (48% vs. 33%), particularly blood bacterial (23% vs. 14%) and fungal (5% vs. 1%) infections. Comparing complications between the later LDLT experience group and DDLT, we still observed significantly higher (all p < 0.04) proportions of recipients with complications after LDLT for biliary leak or biloma (27% vs. 10%), GI bleeding (8% vs. 3%) and bile duct infections (8% vs. 3%). However, significantly lower (all p < 0.04) proportions of recipients with complications were observed among the experienced LDLT group versus DDLT for pneumothorax (0% vs. 2%), pulmonary edema (10% vs. 21%), hepatic encephalopathy (4% vs. 10%), ascites (9% vs. 17%) and fungal pulmonary infections (1% vs. 7%). Table 4 reports 48 p-values, of which 12 are significant (p < 0.05), and 2.4 would be expected to be significant by chance if all tests were independent.

Table 4.  Specific complications of recipients of living donor liver transplants (LDLT) transplanted during periods of less or more center experience (case number ≤20 and case number >20) and deceased donor liver transplants (DDLT)
Complication1(A) LDLT case number ≤ 20 (n = 167)(B) LDLT case number > 20 (n = 217)(C) DDLT (n = 216)p-Value2 A vs. Bp-Value2 B vs. C
n%3n%3n%3
  1. 1Values are missing in less than 3% for each variable.

  2. 2Fisher's exact test was used when any cell had an expected count less than 5.

  3. 3Percent of LDLT case number ≤ 20, LDLT case number >20, or DDLT.

  4. 4Biliary complications include biliary leak/biloma and biliary stricture.

  5. 5Nonsignificant when adjusted for MELD at transplant. In the case of complete separation (pneumothorax), the likelihood ratio test was used.

Surgical complications Biliary complications48450.37735.55324.50.00320.0128
 Biliary leak or biloma6337.75927.22210.20.02435<0.0001
 Biliary stricture3621.63918.03516.20.39630.6090
 Unplanned reexploration6035.94219.43717.10.00050.3757
 Hepatic artery thrombosis148.4115.152.30.19340.1287
 Portal vein thrombosis74.241.800.00.21780.1233
 Intraabdominal bleeding137.8146.5177.90.59560.5393
 Intraabdominal abscesses1710.2177.8115.10.40940.2565
 Ileus53.0115.1104.60.31690.8315
 Bowel obstruction95.441.841.90.05931.0000
 Pneumothorax53.000.052.30.01400.03025
 Wound dehiscence53.052.373.20.75120.5472
 Incisional hernia2213.2188.3188.30.10990.9767
 Inferior vena cava thrombosis00.031.441.90.26061.0000
 Neuropraxia21.231.452.31.00000.5011
Medical complications        
 GI bleeding169.6177.862.80.49990.0195
 Pulmonary edema2414.42210.14520.80.20740.0021
 Respiratory arrest42.473.2156.90.76150.0838
 Hepatic encephalopathy95.494.12210.20.55500.01485
 Myocardial infarction10.620.910.51.00001.0000
 Congestive heart failure21.200.020.90.18690.2448
 Pleural effusion3722.24118.94520.80.39220.5958
 Cardiopulmonary arrest53.031.494.20.30120.0789
 Aspiration53.031.441.90.30271.0000
 Pulmonary embolism10.610.500.01.00001.0000
 Ascites3521.0198.83616.70.00060.01275
 Chronic rejection84.8115.1125.60.90550.8213
 Recurrence of disease, excluding HCV and HCC95.4104.641.90.72720.1030
 Deep vein thrombosis21.220.952.31.00000.2844
Infections Overall infections8047.97233.27333.80.00310.8914
All bacterial infections:6941.37132.76831.50.08270.7827
 Bile duct1911.4177.873.20.23770.0367
 Wound2112.6219.72310.60.36710.7382
 Blood3822.83114.33114.40.03210.9843
 Liver abscess, separate from cholangitis74.241.820.90.22090.6853
 Pulmonary1710.2156.9198.80.25080.4662
 Central nervous system10.610.500.01.00001.0000
 Urinary tract2213.2167.42411.10.05920.1793
All viral infections74.262.8125.60.44350.1458
All fungal infections:2112.6136.02411.10.02440.0567
 Pulmonary53.010.5146.50.08970.0006
 Urinary tract21.252.3125.60.70370.0815
 Wound63.620.931.40.08280.6853
 Bile duct00.020.900.00.50720.4988
 Blood84.820.973.20.02350.1053
 Liver42.410.500.00.17161.0000
 Central nervous system31.810.500.00.32131.0000
Other complications4828.76027.65123.60.76410.3493

Complications graded according to the Clavien scale (Table 1) are shown in Table 5. The majority of complications were grade 1 or grade 2. As shown in Table 5, complications leading to retransplantation or death (Clavien grade 4) occurred more frequently among LDLT recipients (LDLT: n = 61 [15.9%]; DDLT: n = 20 [9.3%]; p = 0.023). Recipients with complications that led to retransplantation were more common in the LDLT group (n = 35; 9.1%) than in the DDLT group (n = 8; 3.7%; p = 0.014). Retransplantation for vascular complications occurred more frequently in LDLT recipients (n = 22; 5.7% vs. n = 2; 1.0%, respectively; p = 0.004). The number of deaths, with or without retransplantation, was not significantly different between the LDLT (n = 34; 5.6%) and DDLT (n = 14; 2.3%; p = 0.30) groups. Although the overall proportion of recipients with biliary complications was higher in the LDLT group, the subset with Clavien grade 4 biliary complications was not significantly different in the two groups (p = 0.47).

Table 5.  Graded complications of living donor (LDLT) and deceased donor (DDLT) recipients: LDLT (n = 384) versus DDLT (n = 216)
ComplicationsClavien grade 1Clavien grade 2Clavien grade 3Clavien grade 4Any Clavien grade
LDLT (%)Retxp and aliveDied w/o retxpRetxp and diedDDLT (%)Retxp and aliveDied w/o retxpRetxp and died
LDLT (%)DDLT (%)LDLT (%)DDLT (%)LDLT (%)DDLT (%)
LDLT (%)DDLT (%)
  1. 1Vascular complications include hepatic artery thrombosis, portal vein thrombosis and inferior vena cava thrombosis.

  2. 2The chi-square test comparing % Clavien grade 4 in LDLT versus DDLT: unplanned reexploration (p = 0.026), vascular complications (p = 0.002).

  3. 3The chi-square test comparing % any Clavien grade in LDLT versus DDLT: any biliary complication (p < 0.001), biliary leak/biloma (p < 0.001), upper/lower GI bleeding (p = 0.006), unplanned reexploration (p = 0.004), hepatic encephalopathy (p = 0.01) and vascular complications (p = 0.03).

Any complication22 (5.7)19 (8.8) 163 (42.5)79 (36.6)33 (8.6) 19 (8.8) 61 (15.9)27 26 820 (9.3) 6122279 (72.7) 137 (63.4)
Any biliary complication14 (3.6)2 (0.9)113 (29.4)38 (17.6)19 (4.9) 7 (3.2)15 (3.9) 5646 (2.8)231161 (41.9)3  53 (24.5)3
 Biliary leak or biloma14 (3.6)2 (0.9) 83 (21.6)15 (6.9) 12 (3.0) 2 (0.9)13 (3.4) 5533 (1.4)021123 (32.0)3  22 (10.2)3
 Biliary stricture 3 (0.8)0 (0)   59 (15.0)26 (12.0)10 (2.6) 6 (2.8)3 (0.8)0123 (1.4)210 75 (19.5)  35 (16.2)
Intraabdominal bleeding 0 (0) 0 (0)  21 (5.5)14 (6.5) 1 (0.3)0 (0)  5 (1.3)3203 (1.4)03027 (7.0) 17 (7.9)
GI bleeding 3 (0.8)1 (0.5)23 (6.0)3 (1.4)2 (0.5)0 (0)  5 (1.3)2212 (0.9)02033 (8.6)3  6 (2.8)3
Intraabdominal abscesses 1 (0.3)0 (0)  20 (5.2)7 (3.2)5 (1.3)3 (1.4)8 (2.1)1521 (0.5)01034 (8.8) 11 (5.1)
Ileus10 (2.6)6 (2.8) 2 (0.5)2 (0.9)2 (0.5)0 (0)  2 (0.5)1012 (0.9)02016 (4.2)  10 (4.6) 
Bowel obstruction 4 (1.0)3 (1.4) 8 (2.1)1 (0.5)1 (0.3)0 (0)  0 (0)  0000 (0)  00013 (3.4)  4 (1.9)
Unplanned reexploration 7 (1.8)2 (0.9) 67 (17.4)27 (12.5)5 (1.3)1 (0.5)16 (4.2)2664 2 (0.9)2020 95 (24.7)3  32 (14.8)3
Hepatic encephalopathy 6 (1.6)4 (1.9) 6 (1.6)10 (4.6) 1 (0.3)4 (1.9)5 (1.3)2214 (1.9)03118 (4.7)3  22 (10.2)3
Ascites18 (4.7)21 (9.7) 21 (5.2)6 (2.8)5 (1.3)6 (2.8)10 (2.6) 1813 (1.4)11154 (14.0) 36 (16.7)
Vascular complications1 0 (0) 0 (0)  11 (2.9)6 (2.8)0 (0)  1 (0.5)24 (6.3)218 24 2 (0.9)220035 (9.1)3  9 (4.2)3
Chronic rejection12 (3.1)8 (3.7) 3 (0.8)2 (0.9)1 (0.3)1 (0.5)3 (0.8)2101 (0.5)01019 (4.9) 12 (5.6)
Recurrent disease-not HCV or HCC 7 (1.8)1 (0.5) 2 (0.5)0 (0)  5 (1.3)1 (0.5)5 (1.3)1222 (0.9)11019 (5.0)  4 (1.9)
Deep vein thrombosis 0 (0) 1 (0.5) 3 (0.8)3 (1.4)0 (0)  0 (0)  1 (0.3)1001 (0.5)010 4 (1.0)  5 (2.3)
Neuropraxia 2 (0.5)1 (0.5) 1 (0.3)0 (0)  2 (0.5)4 (1.9)0 (0)  0000 (0)  000 5 (1.3)  5 (2.3)
Infection17 (4.4)4 (1.9)100 (26.0)58 (26.9)10 (2.6) 3 (1.4)25 (6.5) 219 48 (3.7)170152 (39.6)  77 (33.8)

The effect of center LDLT experience on the occurrence and Clavien grade of recipient complications is shown in Table 6. The proportions of recipients who had any complications, any biliary complications, bile leak or biloma, infection and unplanned reexploration were significantly lower after 20 LDLT cases versus ≤20 LDLT cases. For vascular complications, no significant difference was found after 20 LDLT cases versus ≤20 LDLT cases (7% vs. 11%, p = 0.18). Comparing complications after 20 LDLT cases versus DDLT, the proportions with infection, unplanned reexploration and vascular complications were not significantly different, but any biliary complication and biliary leak or biloma remained significantly higher versus DDLT (p = 0.013 and p < 0.0001, respectively).

Table 6.  Graded complications by transplant type and case number*
Complications Clavien grade 1Clavien grade 2Clavien grade 3Clavien grade 4Any Clavien grade
  1. *p-values from the chi-square test or Fisher's exact test (when any cell had an expected count less than 5).

  2. 1LDLT case number ≤ 20 (n = 167), LDLT case number > 20 (n = 217) and DDLT (n = 216).

Any complication(A) LDLT ≤ 2018 (5%)82 (49%)9 (5%)37 (22%)136 (81%) 
(B) LDLT > 20114 (6%) 81 (37%)24 (11%)24 (11%)143 (66%) 
(C) DDLT119 (9%) 79 (37%)19 (9%) 20 (9%) 137 (63%) 
p-value A vs. B0.48740.02070.04940.00320.0007
p-value B vs. C0.35790.8710.4310.53520.5904
Any biliary complication(A) LDLT ≤ 205 (3%)64 (38%)7 (4%)8 (5%)84 (50%)
(B) LDLT > 209 (4%)49 (23%)12 (6%) 7 (3%)77 (35%)
(C) DDLT2 (1%)38 (18%)7 (3%)6 (3%)53 (25%)
p-value A vs. B0.54990.00080.54880.43270.0035
p-value B vs. C0.03320.19530.24490.78470.013
Biliary leak or biloma(A) LDLT ≤ 206 (4%)46 (28%)3 (2%)8 (5%)63 (38%)
(B) LDLT > 208 (4%)37 (17%)9 (4%)5 (2%)59 (27%)
(C) DDLT2 (1%)15 (7%) 2 (1%)3 (1%)22 (10%)
p-value A vs. B0.96120.01330.18930.18170.0279
p-value B vs. C0.10530.00120.03320.724<0.0001
Infection(A) LDLT ≤ 206 (4%)52 (31%)7 (4%)15 (9%) 80 (48%)
(B) LDLT > 2011 (5%) 48 (22%)3 (1%)10 (5%) 72 (33%)
(C) DDLT4 (2%)58 (27%)3 (1%)8 (4%)73 (34%)
p-value A vs. B0.48570.04590.11 0.0850.0034
p-value B vs. C0.06720.25221.0000.63730.8919
Unplanned reexploration(A) LDLT ≤ 205 (3%)38 (23%)5 (3%)8 (5%)56 (34%)
(B) LDLT > 202 (1%)29 (13%)0 (0%)8 (4%)39 (18%)
(C) DDLT2 (1%)27 (13%)1 (0%)2 (1%)32 (15%)
p-value A vs. B0.24720.01620.0150.59150.0005
p-value B vs. C1.000 0.78880.49880.10530.3749
Vascular complications(A) LDLT ≤ 200 (0%)9 (5%)0 (0%)10 (6%) 19 (11%)
(B) LDLT > 200 (0%)2 (1%)0 (0%)14 (6%) 16 (7%) 
(C) DDLT0 (0%)6 (3%)1 (0%)2 (1%)9 (4%)
p-value A vs. B0.01210.85240.1766
p-value B vs. C0.17510.49880.00230.1526

Center LDLT experience was associated with a significantly lower incidence of grade 4 complications overall (22% vs. 11%; p = 0.003), and a reduced but not significantly lower incidence for each tested subtype of grade 4 complication. The Mantel–Haenszel trend test across the range of Clavien grades was significant only for vascular complications (LDLT case number ≤20 vs. >20: p = 0.0291; LDLT case number >20 vs. DDLT: p = 0.0024).

Because biliary complications occurred at a higher rate in LDLT recipients and were a significant cause of morbidity, two separate logistic regression models were used to investigate risk factors for the development of a biliary leak or of a biliary stricture among LDLT recipients (Table 7A and B). Bivariate and multivariable analyses revealed three variables that were significantly associated with biliary leak. In the multivariable model, a donor with three or more bile ducts was associated with higher risk than that with one duct (AOR = 2.72, p = 0.035) and recipient HCV diagnosis was associated with lower risk than non-HCV (AOR = 0.55, p = 0.011). Center experience was grouped into cases 1–10, 11–20, 21–40 and >40, using case number >40 as the reference group. The risk of biliary leak dropped monotonically with increasing experience (Table 7A). Compared to case number >40, the risk of biliary leak was 126% higher for cases 1–10 (AOR = 2.26, p = 0.015), with a statistically significantly decreasing trend in risk from earlier to later cases by ordinal trend test (p = 0.012).

Table 7.  Logistic regression models fitted to identify significant predictors of biliary leak (A), biliary stricture (B) and Clavien grade 4 complications (C)
 Adjusted odds ratio95% confidence limitsp-Value
  1. 1All variables listed in Table 2 were tested for inclusion in each of the three models above. Among LDLT recipients, n = 78, 89, 109 and 108 transplants were performed for case numbers 1–10, 11–20, 21–40 and >40, respectively.

  2. 2Missing values (n = 22) were assumed to be one bile duct.

A. Predictors of biliary leak1 (among LDLT only) LDLT case number:
 1–10 vs. >402.261.184.340.015
 11–20 vs. >401.770.943.340.079
 21–40 vs. >401.500.812.780.198
 HCV diagnosis0.550.350.870.011
 No. of donor bile ducts from right lobe2: 2 vs. 11.540.992.490.074
 ≥3 vs. 12.721.086.880.035
 Type of anastomosis: Roux-en-Y vs. other0.710.451.130.150
B. Predictors of biliary stricture1 (among LDLT only) LDLT case number:
 1–10 vs. >403.321.457.570.004
 11–20 vs. >401.840.764.470.178
 21–40 vs. >402.371.065.310.036
 Cholestatic liver disease2.101.034.270.040
 Duration of recipient operative procedure (per 100 min)1.331.061.680.014
 Donor hypotension (<100 mmHg)0.450.210.960.038
 No. of donor bile ducts from right lobe2:    
 2 vs. 10.770.421.430.408
 ≥3 vs. 11.570.465.370.470
 Type of anastomosis: Roux-en-Y vs. other0.490.270.880.017
C. Predictors of any grade 4 complication1 (LDLT and DDLT)
 DDLT vs. LDLT case number >400.780.381.640.517
 LDLT case number:    
 1–10 vs. >402.331.065.110.036
 11–20 vs. >402.060.964.420.065
 21–40 vs. >400.960.422.220.921

Two variables were significantly associated with biliary stricture (duration of recipient operation and Roux-en-Y biliary reconstruction) in bivariate analyses. In the multivariable logistic regression model, five variables were significant: recipient diagnosis of cholestatic liver disease (AOR = 2.10, p = 0.040) and duration of recipient operation (AOR = 1.33 per 100 min, p = 0.014) were associated with higher risk. Two variables were associated with a lower risk of biliary stricture: use of a Roux-en-Y reconstruction (AOR = 0.49, p = 0.017) and donor hypotension (AOR = 0.45, p = 0.038). Finally, as with biliary leak, there was a significantly higher risk of biliary stricture during early center experience (Table 7B). Cold ischemia time was not a significant predictor of either biliary leak or biliary stricture.

Predictors of grade 4 complications among LDLT and DDLT recipients were investigated in a third logistic regression analysis (Table 7C). This model showed that patients who underwent LDLT during a center's earlier experience (<20 LDLT) had more than two-fold the odds of developing a grade 4 complication compared to those who underwent LDLT once the center had done >40 LDLT cases (cases 1–10: AOR = 2.33, p = 0.036). There was a statistically significantly decreasing trend in risk of grade 4 complications from earlier to later cases by ordinal trend test (p = 0.008).

In a separate model of grade 4 complications restricted to LDLT recipients, each of the donor factors in Table 2 were tested and none was found to be significant, including the graft weight to recipient weight ratio <0.8.

There was no difference in the odds of a grade 4 complication between DDLT recipients and LDLT recipients transplanted after centers had performed at least 40 cases (AOR = 0.78, p = 0.52). Although cold ischemia time could not be tested in this model because of confounding with transplant type, we tested its effect in separate models for LDLT and DDLT. In each case, longer cold ischemia time (as a continuous variable) was associated with significantly higher odds of grade 4 complications (LDLT: AOR = 1.26/h, p = 0.005; DDLT: AOR = 1.17/h, p = 0.009).

Discussion

Despite its introduction for pediatric patients nearly 20 years ago (12), the use of living donors for liver transplantation in adults has emerged more slowly. Interest in adult-to-adult LDLT increased as experience with the procedure grew in Japan and Korea, where deceased donor organs were not readily available. The increased use of split livers in the United States and Europe also contributed to the surgical skills needed to successfully perform the LDLT procedure (13). Unlike living donor kidney transplantation, where advantages of living donor over deceased donor grafts have been demonstrated in both recipient and graft survival, and where the safety of the donor operation has been documented, LDLT is still under a high level of scrutiny (14,15).

The A2ALL network was established to better assess the safety of the LDLT procedure for both donors and recipients, and to better define the situations where the procedure should be considered as an option. One primary study aim was to establish the rates of various complications for both donors and recipients in order to properly inform patients as they make decisions relating to the pursuit of living donor transplant. An important finding from the A2ALL group was the demonstration of a significant survival benefit for potential recipients when they chose to pursue living donor transplant versus remaining on the waiting list for DDLT (16). This advantage was most clear after the transplant center had done at least 20 LDLT procedures. A lingering question, however, has been the rate of complications experienced by recipients of the LDLT, and how these rates compare with DDLT. This report is the first to compare the two groups, using a cohort of recipients who all shared the common feature of having at least one donor who completed a history and physical examination for potential LDLT.

In this and other series, LDLT recipients were less ill in general than their DDLT counterparts at the time of transplantation. In the early reported experience with LDLT, it was observed that patients who had more decompensated liver disease did less well with LDLT (17). In the period of time covered by our study, two different organ allocation schemes for DDLT were in effect, the older system utilizing hospital or ICU status and Child-Turcotte-Pugh score to determine ranking on the waiting list, and the MELD system since February 2002. Although our LDLT and DDLT recipients were comparable at study enrollment, which was the date of the potential donor's history and physical examination (16), MELD score at the time of transplant was higher in recipients of DDLT, since the latter group had a longer time until transplant. A significantly higher proportion of DDLT recipients were in the ICU and/or on dialysis at the time of transplant. This may explain the higher infection rates in DDLT recipients, since they had longer and possibly more complex pretransplant hospital stays.

The most important differences in posttransplant morbidity between recipients of LDLT and DDLT were seen in surgical complications. Biliary complications (especially biliary leak), vascular complications and unplanned reexplorations were observed at higher frequencies in LDLT recipients. Other authors have noted higher biliary and vascular complication rates among LDLT recipients compared to historic DDLT controls (18). Possible explanations include the greater technical demands of LDLT, inferior quality of the LDLT graft and the caliber of LDLT donor vessels available for anastomosis (19–25). An added dimension of this study was the systematic use of the Clavien grading system to characterize the severity of complications. In our analyses, these surgical complications led to a higher rate of retransplantation and death (Clavien grade 4) among LDLT recipients compared to DDLT recipients. The overall rate of biliary complications in LDLT recipients was 42.2% versus 24.5% in DDLT recipients, and many of these complications required repeated endoscopic or percutaneous transhepatic interventions. Such information should be helpful when counseling patients about the option of LDLT.

Possible explanations for the higher rate of biliary complications after LDLT (and proposed solutions) have been described (26,27). One study characterized preoperative and intraoperative findings that were associated with a higher rate of biliary complications (28). In the current study, certain technical details of the biliary reconstruction were captured. Having three or more bile ducts in the liver graft was associated with higher risk of biliary leak. Preoperative imaging and determination of the planned line of transection through the liver may permit predictions about the number of ducts that may require anastomosis. If the proposed graft is expected to yield three or more ducts, consideration could be given to selecting a different donor, or at least counseling the recipient about the higher risk of leak. In terms of biliary stricture, the use of a Roux-en-Y anastomosis was associated with a lower odds of stricture formation, as was donor hypotension. We are unable to ascribe a causative relationship between the anastomotic technique and the occurrence of biliary stricture, since the choice of technique is often dictated by operative findings. The best technique for reconstruction continues to be a topic of debate (29–32), and given limited details in our retrospective data collection, it may be premature to suggest that a Roux-en-Y should be done in every case. The basis for the association between biliary stricture and donor hypotension is unclear. Data currently being collected in the A2ALL Prospective Cohort Study may illuminate both of these issues in the future.

The level of experience with a procedure, especially one as complicated as LDLT, should be considered in analyses of outcomes. Thus, in the current study, the adjusted odds of a biliary leak or stricture were higher when centers had not yet performed 40 LDLT. The rate of biliary stricture after DDLT, for which techniques of biliary reconstruction are well established, has been reported in 10–30% of recipients. This suggests that the rate of this complication after LDLT may be difficult to reduce further (33). The inability to accurately assess the viability of biliary tissue at the time of anastomosis may contribute to this problem.

Another important finding related to center experience was the lack of difference in the odds of Clavien grade 4 complications (defined as leading to retransplantation or death) between DDLT and LDLT recipients once the center had performed more than 20 LDLT cases. This finding is consistent with the improved survival seen with LDLT in experienced centers versus remaining on the waitlist for a DDLT (16). In both LDLT and DDLT, we found a significant relationship between cold ischemia time and the likelihood of grade 4 complications. This is consistent with our previous identification of cold ischemia time as a significant predictor of the overall risk of LDLT graft failure, and further emphasizes the unique importance of even the comparatively short cold ischemia times associated with LDLT transplantation (11). When patients are evaluated and treatment options are reviewed, these aspects should be considered by the patient and caregivers in the decision whether to proceed with LDLT.

We have previously shown that graft size in the A2ALL retrospective cohort was not associated with a significantly higher risk of graft failure (11), and in the current study, the low graft weight to recipient weight ratio (<0.8) was not a significant predictor of bile leak, biliary stricture or grade 4 complications.

Many advances in LDLT have occurred over the last decade, but its exact place in the treatment armamentarium for patients with end-stage liver disease and liver cancer is still being defined. This study not only provided details on complications of liver transplantation but also defined complications that are more frequent in LDLT. Despite a higher rate of complications among LDLT recipients, complications requiring retransplantation or leading to death were not significantly higher in LDLT once centers were experienced with the procedure. This finding, in concert with our previous conclusion that choosing LDLT over continuing on the waitlist leads to a survival advantage in experienced centers, underscores the impact of the learning curve on this highly technical procedure. Potential LDLT recipients need to hear about the rates of complications, and this study will help to define those rates. The decision to proceed, however, must be balanced against the possibility of deteriorating or dying while on the waitlist. We acknowledge that in this study the LDLT recipients had relatively low MELD score at transplant and our results may not be applicable to patients who are more ill. As the practice of LDLT matures, it will be important to continually reevaluate the morbidity associated with the operation and identify opportunities to improve its outcomes.

Acknowledgments

This study was supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK grant numbers U01-DK62536, U01-DK62444, U01-DK62467, U01-DK62483, U01-DK62484, U01-DK62494, U01-DK62496, U01-DK62498, U01-DK62505, U01-DK62531) through cooperative agreements (listed below). Additional support was provided by the U.S. Department of Health Resources and Services Administration (HRSA) and the American Society of Transplant Surgeons (ASTS). This study was presented in part at the 57th annual meeting of the American Association for the Study of Liver Diseases, Boston, MA, October 2006.

Appendix

The following individuals were instrumental in the planning, conduct and/or care of patients enrolled in this study at each of the participating institutions as follows:

Columbia University Health Sciences, New York, NY (DK62483): PI: Jean C. Emond, MD; Co-PI: Robert S. Brown, Jr., MD, MPH; Study Coordinators: Rudina Odeh-Ramadan, PharmD; Scott Heese, BA

Northwestern University, Chicago, IL (DK62467): PI: Michael M.I. Abecassis, MD, MBA; Co-PI: Andreas Blei, MD; Study Coordinator: Patrice Al-Saden, RN, CTCC

University of Pennsylvania Health System, Philadelphia, PA (DK62494): PI: Abraham Shaked, MD, PhD; Co-PI: Kim M. Olthoff, MD; Study Coordinators: Mary Kaminski, PA-C; Mary Shaw, RN, BBA

University of Colorado Health Sciences Center, Denver, CO (DK62536): PI: James F. Trotter, MD; Co-PI: Igal Kam, MD; Study Coordinators: Carlos Garcia, BS

University of California Los Angeles, Los Angeles, CA (DK62496): PI: Ronald W. Busuttil, MD, PhD; Co-PI: Sammy Saab, MD; Study Coordinator: Janet Mooney, RN, BSN

University of California San Francisco, San Francisco, CA (DK62444): PI: Chris E. Freise, MD, FACS; Co-PI: Norah A. Terrault, MD; Study Coordinator: Dulce MacLeod, RN

University of Michigan Medical Center, Ann Arbor, MI (DK62498): PI: Robert M. Merion, MD; DCC Staff: Anna S.F. Lok, MD; Akinlolu O. Ojo, MD, PhD; Brenda W. Gillespie, PhD; Margaret Hill-Callahan, BS, LSW; Terese Howell, BS; Lan Tong, MS; Tempie H. Shearon, MS; Karen A. Wisniewski, MPH; Monique Lowe, BS

University of North Carolina, Chapel Hill, NC (DK62505): PI: Paul H. Hayashi, MD; Study Coordinator: Carrie A. Nielsen, MA

University of Virginia (DK62484): PI: Carl L. Berg, MD; Co-PI: Timothy L. Pruett, MD; Study Coordinator: Jaye Davis, RN

Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond, VA (DK62531): PI: Robert A. Fisher, MD, FACS; Co-PI: Mitchell L. Shiffman, MD; Study Coordinators: Ede Fenick, RN; April Ashworth, RN

National Institute of Diabetes and Digestive and Kidney Diseases, Division of Digestive Diseases and Nutrition, Bethesda, MD: James E. Everhart, MD; Leonard B. Seeff, MD; Patricia R. Robuck, PhD; Jay H. Hoofnagle, MD

Supplemental data included here have been supplied by the Arbor Research Collaborative for Health as the contractor for the Scientific Registry of Transplant Recipients (SRTR). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy of or interpretation by the SRTR or the U.S. Government.

Ancillary